explore -WSS

explore

author：comprehensive 2025-09-02 22:01:25 - browse：331

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Readout LOUD podcast: A CRISPR milestone, biotech mixology

WSS

STAT Readout: Friday, Oct. 20 biotech updates

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Childhood cancer progress stalls for Black, Hispanic kids: Report

A daunting task: navigating dual Medicare, Medicaid eligibility

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

focus

explore

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

Ransomware attacks on hospitals: Study outlines patient impact

How to save PrEP access — and even expand it

Why medical students are struggling with mental health

State Dept. review finds Biden bears some blame for Afghanistan failures

Is there really a nursing shortage in the U.S.?

State Dept. review finds Biden bears some blame for Afghanistan failures

J&J lung cancer data amount to new salvo against AstraZeneca

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why a market frenzy over new weight loss drugs defies logic

Wikipedia

ADCs take center stage as promising cancer treatments

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Poor hospice wound care hurts patients and families

Merck, Daiichi strike cancer drug pact worth up to $22 billion

STAT Summit: The economic case for universal basic health care

knowledge

entertainment

entertainment

hotspot